BRAVISSIMO: 12-month results from a large scale prospective trial.

BRAVISSIMO: 12-month results from a large scale prospective trial. J Cardiovasc Surg (Torino). 2013 Apr;54(2):235-53 Authors: Bosiers M, Deloose K, Callaert J, Maene L, Beelen R, Keirse K, Verbist J, Peeters P, Schroë H, Lauwers G, Lansink W, Vanslembroeck K, D'archambeau O, Hendriks J, Lauwers P, Vermassen F, Randon C, Van Herzeele I, De Ryck F, De Letter J, Lanckneus M, Van Betsbrugge M, Thomas B, Deleersnijder R, Vandekerkhof J, Baeyens I, Berghmans T, Buttiens J, Van Den Brande P, Debing E, Rabbia C, Ruffino A, Tealdi D, Nano G, Stegher S, Gasparini D, Piccoli G, Coppi G, Silingardi R, Cataldi V, Paroni G, Palazzo V, Stella A, Gargiulo M, Muccini N, Nessi F, Ferrero E, Pratesi C, Fargion A, Chiesa R, Marone E, Bertoglio L, Cremonesi A, Dozza L, Galzerano G, De Donato G, Setacci C Abstract The BRAVISSIMO study is a prospective, non-randomized, multi-center, multi-national, monitored trial, conducted at 12 hospitals in Belgium and 11 hospitals in Italy. This manuscript reports the findings up to the 12-month follow-up time point for both the TASC A&B cohort and the TASC C&D cohort. The primary endpoint of the study is primary patency at 12 months, defined as a target lesion without a hemodynamically significant stenosis on Duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without target lesion revascularization (TLR) within 12 months. Between July 2009 and September 2010, 190 patients with TASC A or TASC B...
Source: The Journal of Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: J Cardiovasc Surg (Torino) Source Type: research